Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
Next >
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
June 21, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
June 16, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
May 31, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
May 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
May 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
April 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
April 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
April 13, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
March 25, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
March 14, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 17, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
February 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
February 02, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
January 18, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
January 09, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
January 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
January 05, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Elects Jacqueline Wright to Its Board of Directors
December 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
December 15, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
November 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
November 09, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
November 03, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
October 14, 2021
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.